Generation of human induced pluripotent stem cells carrying a safety bet for cell-based therapy in Parkinson’s disease
Objective: To increase the safety of future cell-based therapy in Parkinson's disease, we generated human induced pluripotent stem cells (hiPSCs) possessing a safety switch via…Comparison of two protocols for neural induction and cultivation of iPSCs derived neural stem cells
Objective: Our objective was to establish and evaluate a protocol for deriving proliferative neural cultures from induced pluripotent stem cells (iPSC). Background: For generating patient…Functional characterisation and the selective vulnerability of SNCA (A30P) patient-derived midbrain dopaminergic neurons to ER stress
Objective: To functional characterise and phenotype the genetic Parkinson's disease (PD) patient with an A30P point mutation in SNCA using midbrain dopaminergic neurons (mDANs) vs…Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease
Objective: In this study, we aim to generate and characterise patient-derived midbrain dopaminergic neurons (mDANs) of the A30P Parkinson's disease (PD) familial case. Our goal…Clinical and neuroimaging outcomes up to 18 years after fetal tissue transplant for Parkinson’s disease
Objective: To characterize clinical and radiological outcomes in 4 patients with Parkinson's disease (PD) at 16-18 years post-transplant of fetal ventral mesencephalic (fVM) tissue into…Unconventional chaperone inhibits alpha-synuclein amyloid formation by promoting off-pathway aggregation
Objective: To find new potential druggable targets that prevent alpha-synuclein aggregation and toxicity in Parkinson's disease. Background: Alpha-synuclein (aS) is the primary protein deposited in…Parkinson’s disease-associated Miro1 mutants cause mitochondrial dysfunction
Objective: In the present study we dissected the role of the first PD-associated mutations in RhoT1, the gene encoding for Miro1. Background: Commonly involved pathogenic…A descriptive study on the safety and feasibility of mesenchymal stem cell therapy for Parkinson’s disease: A case series
Objective: To describe the incidence and severity of infusion-related adverse events of mesenchymal stem cells (MSC) for Parkinson's disease in patients who underwent treatment. Background:…Polyethylenimine (PEI) nanoparticle-mediated delivery of siRNA to silence neuronal gene expression of alpha-synuclein in a mouse model of Parkinson’s disease
Objective: To develop novel therapeutic strategies for movement disorders by interfering with neuronal gene expression, PEI nanoparticle-mediated delivery of RNA was investigated in vivo. Background:…Gene delivery of AAV2-neurturin for patients with Parkinson’s disease: A meta-analysis
Objective: The objectives of this meta-analysis are: 1) to investigate the efficacy of AAV2-neurturin gene delivery for patients with Parkinson's disease; 2) to compare AAV2-neurturin…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.